MGI Tech Launches 'SEQ ALL' Full-Read-Length Sequencing Refresh Program: More Reliable, Comprehensive, and High-Quality Domestic Sequencing Solutions

Since the launch of the first domestically produced sequencer based on DNBSEQ technology in 2015, nearly a decade has passed. Today,MGI is not only capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput levels, from gigabase (Gb) to terabase (Tb), but has also become the only institution globally to possess all three gene sequencing technologies and corresponding products: “excited fluorescence,” “self-luminescence,” and “non-luminescent.”As a pioneer in China’s gene sequencing sector, MGI is committed to providing users with precise, efficient, and reliable sequencing solutions.

MGI’s DNBSEQ™ sequencing technology leverages fundamental advantages, including low error accumulation from rolling circle replication amplification and high signal acquisition efficiency from patterned array chips. It demonstrates benefits such as absence of PCR error accumulation, high accuracy, low duplication rates, higher data utilization, and lower mismatch rates, establishing it as an industry benchmark. In 2024, MGI launched its next-generation sequencing reagent, StandardMPS 2.0, further elevating sequencing accuracy to the new Q40 standard and providing users with higher-quality solutions. As of the end of 2024, based on DNBSEQ^™The platform has published more than 10,000 articles.With the launch of the CycloneSEQ nanopore sequencing technology in September 2024, MGI has achieved a powerful synergy between long-read and short-read sequencing technologies.

MGI not only boasts significant advantages in technology and products but also possesses a comprehensive after-sales support system that provides users with all-around service assurance. Leveraging its superior product performance and robust service framework, MGI has garnered increasing recognition and trust from users. As of June 30, 2024, MGI’s business presence spans over 100 countries and regions across six continents, with nine global R&D centers, seven production bases, nine international warehouses, and more than ten customer experience centers established worldwide, serving a cumulative base of over 3,000 customers.

Leveraging robust R&D capabilities and a comprehensive quality management system,All of MGI’s released low-, medium-, and high-throughput DNBSEQ sequencing platforms have obtained medical device registration certificates from the National Medical Products Administration (NMPA), qualifying them for clinical applications. Among the gene sequencers currently approved by the NMPA for clinical testing in China, as many as 23 models are based on MGI’s DNBSEQ sequencing technology.

Furthermore, since 2023, MGI has launched the DCS Lab Research Empowerment Program. By assisting global researchers in establishing internationally leading, large-scale, and standardized multi-omics frontier laboratories, the program promotes research and development in genomics, cytomics, and spatial omics (corresponding to “DNA Omics,” “Cell Omics,” and “Spatial Omics” in “DCS Lab,” respectively), thereby accelerating the empowerment of life sciences with emerging technologies.Currently, DCS Lab has established over 15 facilities worldwide, with sites inaugurated at the Shanghai Center for Brain Science and Brain-Inspired Technology, Haihe Laboratory of Cell Ecosystem, National Cancer Centre Singapore, Peking University Institute of Advanced Agricultural Sciences, Fujian Medical University, National Center for Model Animal Sciences at China Agricultural University, and Hefei Institute of Health and Big Data, among others.。

Over nearly a decade of steadfast advancement, MGI has meticulously crafted a comprehensive product portfolio spanning high-, mid-, and low-throughput platforms.Promoted DNBSEQ-based "short-read" sequencers to more than 80 countries and regions worldwide, and ranked first in China for two consecutive years in terms of newly installed market share of sequencing equipment.

The DNBSEQ-E25 (hereinafter referred to as “E25”) is the world’s first genetic sequencer based on the biochemical principle of self-luminescent sequencing.It occupies a desk area of only 0.1m²², compatible with sequencing consumables of varying read lengths, it can output sequencing data within 5–20 hours. With its simple operation, compact portability, and low requirements for operating environments, the E25 significantly lowers the barrier to entry for sequencing, becoming a gene sequencer that is “readily available anywhere” and “accessible to everyone.”E25: “Mountain-to-Sea Versatility,” “Plug-and-Play” — Cost-effective for small-scale sequencing scenarios, it is an ideal tool for medium and small hospitals, CDCs at all levels, customs authorities, and mid-sized laboratories to easily establish their sequencing capabilities.

The DNBSEQ-G99 (hereinafter referred to as “G99”) is one of the fastest models among current small- to medium-throughput sequencers worldwide.The G99 has optimized and enhanced multiple core systems, including biochemistry, fluidics, optics, and temperature control, enabling PE150 sequencing to be completed within 12 hours. It also features an integrated computing module, achieving seamless integration of sequencing and bioinformatics analysis.The G99 is widely used in settings with high demands for sequencing throughput and speed, such as research institutions and large hospitals. It is suitable for tumor targeted sequencing with small sample sizes, small-scale whole-genome sequencing, low-depth WGS, individual identification, and 16S metagenomic sequencing.With the release of PE300 sequencing reagents, the G99 offers users expanded sequencing possibilities to meet diverse sequencing needs.

The MGISEQ-2000 is a versatile, flexible-throughput desktop sequencer that supports the simultaneous loading of 1–2 flow cells per run. Flow cells of different specifications (FCS small flow cells and FCL large flow cells) operate independently, enabling flexible adaptation to more than 20 application scenarios, ranging from reproductive health testing and rapid pathogen detection to tumor profiling, single-cell sequencing, whole-genome sequencing (WGS), and whole-exome sequencing (WES).

In addition, the MGISEQ-2000RS via software upgradeAdded multiplex immunofluorescence staining and imaging capabilities, enabling dual functionality for genomics research and spatial proteomics data acquisition.As an “all-in-one” sequencer, the MGISEQ-2000 is not only widely popular in the Chinese market,It has also obtained market access approvals in more than 90 countries and regions worldwide.

DNBSEQ-T7 (hereinafter referred to as “T7”) is a high-performance, high-throughput gene sequencer launched by MGI. It boasts an ultra-high data output capacity of up to 7 Tb per day, adopts a four-lane flow cell platform that supports independent operation of 1–4 flow cells, and enables seamless integration of multiple sequencing runs within 24 hours, allowing for the sequencing of more than 14,000 human whole genomes annually.Recently, MGI has officially completed performance optimization and algorithm upgrades for the T7 high-throughput gene sequencer, enabling high-quality sequencing of methylation libraries and expanding the T7’s applicability in epigenomics.

DNBSEQ-T20×2 (hereinafter referred to as “T20”) is an ultra-high-throughput sequencer launched by MGI. It supports the simultaneous operation of six flow cells, achieving a single-run throughput of up to 42 Tb (PE100) or 72 Tb (PE150). Designed to meet the most challenging sequencing demands, it aims to support large-scale genomics projects worldwide.The T20 can perform 50,000 human whole-genome sequencing runs annually. By employing innovative immersion-based biochemical reaction technology, it reduces the cost of single-person whole-genome sequencing to under $100, setting new global records for both throughput and per-sample cost in gene sequencing instruments, and providing the industry with a “super sequencing factory.”

On September 9, 2024, BGI Group grandly unveiled its latest sequencing technology—CycloneSEQ Sequencing Technology—along with two compact, high-performance next-generation sequencers: the nanopore sequencers CycloneSEQ-WT02 and CycloneSEQ-WY01.With the official launch of the first nanopore sequencer representing the “long-read” technology pathway, MGI, as the global distributor of the CycloneSEQ nanopore sequencer, has achieved a closed-loop portfolio of “full-length” sequencing products, ushering in a new chapter for the gene sequencing industry.

CycloneSEQ-WT02 (hereinafter referred to as “WT02”) is a mid-throughput nanopore sequencer launched by MGI’s Xunfeng brand. Compact and portable, it features a dual-chip architecture, supports independent operation, and offers flexible throughput options.This instrument boasts superior performance features, including ultra-long read lengths (at the megabase pair level), real-time sequencing, and sustained continuous sequencing. Its three major advantages are “comprehensive coverage, rapid reading, and flexible sequencing.”WT02 has a wide range of applications in the life sciences sector. Currently, the applications of the WT02 sequencer coverResearch fields such as epigenomics, transcriptomics, spatial-temporal omics, and chromatin structure analysis, as well as clinical areas including birth defect prevention and control, tumor detection, and rapid pathogen testing.

CycloneSEQ-WY01 (hereinafter referred to as “WY01”) is a high-throughput nanopore sequencer jointly developed by MGI and BGI Xufeng, scheduled for official release in March 2025.It is equipped with high-density chips and features ultra-high throughput, enabling capabilities such as ultra-long read lengths, real-time sequencing, and sustained continuous sequencing.With superior performance,WY01 inLarge-scale genome sequencing, human whole-genome resequencing, genome assembly, full-length transcriptome sequencing, and epigenome sequencingdemonstrating broad application potential across multiple scenarios.

Based on the aforementioned sequencing platforms, MGI provides SEQ ALL, a comprehensive end-to-end solution spanning from sample extraction to data analysis. Meanwhile, MGI has successively launched multiple sequencing library preparation reagent kits,These reagent kits are deeply integrated with sequencers, better matching users' diverse application scenarios and covering various sequencing library types, including DNA, exome, RNA, and methylation. Furthermore,MGI offers its App series products, which are compatible with libraries prepared using various adapters and demonstrate strong compatibility. These products can convert libraries prepared using third-party library preparation kits, enabling sequencing on MGI’s sequencing platforms.

Looking ahead, centered on the “reading, writing, and storing” of life, and with “SEQ ALL” (full-length sequencing) as its goal, MGI will continue to provide advanced, user-friendly, and accessible core tools for life sciences. It will steadily expand its marketing network and technical support coverage, empowering global life science research and the development of healthcare, and driving life sciences technology into households worldwide.

Currently,MGI’s Global Customer Experience Centers have all launched its core sequencing platforms. We cordially invite ecosystem partners and users to visit for hands-on experience and trials, allowing you to witness MGI’s cutting-edge technologies and innovative products firsthand, and gain a deeper understanding of how our comprehensive product solutions can empower your research and application projects.We look forward to partnering with you to explore the boundless possibilities of genetic technology and drive the continuous advancement of life sciences.

MGI: Providing You with More Reliable Choices!

Scan to Apply

Select "Reliable"